A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact clinical care. Research into new or repurposed treatments that target this new ...

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and adults. It is characterized by failures in the maturation of T-lymphocytes, ...

Relapsed and refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) remains a significant challenge in pediatric oncology. Despite advances in front-line therapies that have improved survival ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Despite the remarkable clinical successes of chimeric antigen receptor (CAR) T-cell therapies in treating B-cell malignancies and multiple myeloma, similar outcomes have not been achieved in other ...

CAR-T – chimeric antigen receptor T-cell – therapy is a type of immunotherapy specifically developed for each individual patient and involves genetically reprogramming the patient’s own immune system ...

Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster presentations for CT0596 (an allogeneic CAR T-cell ...

New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients. This is an ASCO Meeting Abstract from the ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with manageable side effects. In an onsite interview with CURE at the 2025 ASH ...